Saturday 17 October 2026
Export ANAB’s income statement to Excel — free account
AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
46.61
2.10
−4.31%
Follow ANAB
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 3 | 5 | 6 |
| 760.85% | (308.02%) | (24.49%) | (114.55%) | ||
| (34.77%) | (19.99%) | (3.12%) | (7.13%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(51.39%) | (28.78%) | (4.23%) | (9.72%) | |
Average Days of Receivables |
63.47 | 163.01 | 52.66 | 40.44 | |
Free Cash Flow per Share |
(4.45) | (5.22) | 0.68 | 0.15 | |
Free Cash Flow |
(128.08) | (145.32) | 19.61 | 4.41 | |
Capital Expenditures |
(0.37) | (0.35) | (0.09) | (0.07) | |
| Other line items | |||||
Cash ROIC |
(57.96%) | (66.19%) | 5.62% | 1.47% | |
Accounts Receivable Turnover |
8.10 | 3.86 | 6.29 | 10.65 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
133.00% | 90.28% | 57.96% | 55.42% | |
Selling, General and Administrative Expense of Revenue |
36.94% | 26.64% | 21.63% | 27.03% | |
Share Based Compensation of Revenue |
28.24% | 21.10% | 15.38% | 17.69% | |
Operating CF/Net income |
0.96 | 1.71 | (1.49) | (0.17) | |
Depreciation/Fixed assets |
(3.52) | (2.85) | (1.69) | (0.51) | |
Capex/Depreciation |
0.06 | 0.08 | 0.04 | 0.11 | |
Revenue per Share |
4.28 | 6.09 | 8.16 | 8.10 | |
Operating CF per Share |
(4.43) | (5.21) | 0.68 | 0.16 | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates